Related Experiment Video
Updated: Jun 22, 2026

Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking
Published on: August 29, 2018
Focus on the ONTARGET results
1Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. henrylelliott@aol.com
Abstract:
Blockade of the renin-angiotensin system (RAS) has become an integral component of the treatment of patients at increased cardiovascular risk. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) studied 23 400 high-risk cardiovascular patients and compared the effectiveness of telmisartan with that of ramipril and showed that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only angiotensin II blocker with clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is widely regarded as the 'reference' drug for RAS blockade in patients at increased cardiovascular risk. Despite the prior exclusion of patients intolerant of angiotensin-converting enzyme inhibitors drugs, there were fewer discontinuations in the telmisartan group, and so telmisartan had a superior overall efficacy/tolerability ratio.
Insights
Telmisartan and ramipril demonstrated equivalent cardiovascular protection in high-risk patients. Telmisartan showed better tolerability, with fewer discontinuations, making it a strong option for renin-angiotensin system blockade.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Renin-angiotensin system (RAS) blockade is crucial for managing patients with high cardiovascular risk.
- Ramipril is a widely accepted 'reference' drug for RAS blockade.
Purpose of the Study:
- To compare the cardiovascular protection of telmisartan versus ramipril in high-risk patients.
- To evaluate the overall efficacy and tolerability of telmisartan compared to ramipril.
Main Methods:
- The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) involved 23,400 high-risk cardiovascular patients.
- Direct comparison of telmisartan and ramipril effectiveness and tolerability.
Main Results:
- Telmisartan and ramipril were found to be therapeutically equivalent in providing cardiovascular protection.
- Telmisartan exhibited a superior overall efficacy/tolerability ratio due to fewer patient discontinuations.
Conclusions:
- Telmisartan is the only angiotensin II blocker with demonstrated cardiovascular protection equivalent to ramipril.
- Telmisartan offers a favorable efficacy and tolerability profile for RAS blockade in high-risk individuals.
More Related Videos
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Focusing of Light in the Eye
Methods of Documentation IV: Focus Charting
It typically involves three columns for recording information:
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...

